

**S4 Table. Number of recommendations, the quality of CPGs reporting them, and the frequency with which each drug class and individual LMWH agents were discussed, by indication.**

Indication (# RECs)	# RECs by evidence level	# times LMWH and FDP mentioned (%)	CPG quality # (%)
<b>Treatment of:</b>			
Symptomatic, acute, VTE in cancer patients (k=40)	Level A: 13 (33) Level B: 6 (15) Level C: 12 (30) Level D: 9 (23)	LMWH: 36 (73) dalteparin: 3 (6) enoxaparin: 2 (4) tinzaparin: 4 (8) FDP: 4 (8)	High: 4 (33) Moderate: 5 (42) Low: 3 (25)
DVT in pregnant and/or lactating females (k= 19)	Level A: 3 (16) Level B: 9 (47) Level C: 4 (21) Level D: 3 (16)	LMWH: 17 (89) FDP: 2 (11)	High: 2 (29) Moderate: 1 (14) Low: 3 (43)
DVT in non-cancer patients (k=15)	Level A: 3 (20) Level B: 5 (33) Level C: 7 (47) Level D: 0	LMWH: 13 (72) FDP: 5 (28)	High: 4 (57) Moderate: 2 (29) Low: 1 (14)
DVT in patients who failed treatment with warfarin (k=6)	Level A: 1 (17) Level B: 0 Level C: 5 (83) Level D: 0	LMWH: 6 (67) FDP: 3 (33)	High: 2 (50) Moderate: 2 (50) Low: 0
DVT in patients who cannot tolerate warfarin or it is contraindicated (k=1)	Level A: 0 Level B: 1 (100) Level C: 0 Level D: 0	LMWH: 1 (100) FDP: 0	High: 0 Moderate: 0 Low: 1 (100)
<b>Prevention of:</b>			
VTE for patients undergoing non-orthopedic surgery (k=48)	Level A: 20 (42) Level B: 19 (40) Level C: 9 (19) Level D: 0	LMWH: 46 (77) dalteparin: 1 (2) enoxaparin: 1 (2) bevimarin: 1 (2) FDP: 11 (18)	High: 5 (63) Moderate: 1 (13) Low: 2 (25)
VTE in cancer patients (k=19)	Level A: 4 (21) Level B: 9 (47) Level C: 5 (26) Level D: 1 (5)	LMWH: 17 (68) dalteparin: 2 (8) enoxaparin: 3 (12) tinzaparin: 1 (4) nadroparin: 1 (4) FDP: 1 (4)	High: 3 (33) Moderate: 3 (33) Low: 3 (33)
Post-operative VTE for patients undergoing orthopedic surgery of the lower limbs (k=12)	Level A: 5 (42) Level B: 7 (58) Level C: 0 Level D: 0	LMWH: 11 (58) FDP: 8 (42)	High: 1 (50) Moderate: 1 (50) Low: 0
<b>Peri-operative bridging for:</b>			
Patients who require long-term warfarin and must discontinue due to surgery (k=8)	Level A: 4 (50) Level B: 4 (50) C: 0 D: 0	LMWH: 8 (100) FDP: 0	High: 2 (50) Moderate: 1 (25) Low: 1 (25)

**Abbreviations:** RECs: recommendations; CPG= clinical practice guideline, LMWH= low molecular weight heparin, FDP= fondaparinux  
Evidence level A: high-quality evidence; B: moderate-quality evidence; C: low quality evidence; D: expert opinion/consensus

NB: We did not identify any recommendations for the prevention of post-operative DVT in patients undergoing hip or knee surgery and cannot use warfarin